FIRE reported an ORR of 89.6% in the overall CLL patient group at a follow-up of 21.6 months in a population of patients with 58.7% del17p and/or TP53 mutations [17]. The gene discussed is TP53; the disease is B-cell chronic lymphocytic leukemia.